|
| |
Acorda TherapeuticsAcorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial development efforts on a range of therapeutics for individuals with chronic, or long term, SCI. Currently, there is no therapy that improves neurological function in chronic SCI patients.
However, Acorda's clinical stage product, Fampridine-SR, has improved neurological function for patients with chronic SCI in Phase 2 clinical trials. The Company believes that the therapeutic products it develops for SCI are likely also to have applications in other neurological conditions-for example, both Fampridine-SR and the Company's M1 monoclonal antibody ("M1") product have shown promise as therapies for multiple sclerosis ("MS"). Other potential markets for the Company's products include traumatic brain injury, Parkinson's disease and stroke.
| Contact Details: |
| 15 Skyline Drive |
| Hawthorn |
| |
| 10532 |
| United States of America |
| Tel: | 914-347-4300 |
| Fax: | 914-347-4560 |
| Email: | info@acorda.com |
| WWW: | www.acorda.com/
|
| |
Recent Publications by Acorda Therapeutics: |  |
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
OBJECTIVE: To examine the efficacy and safety of three different doses of... | 2nd August, 2008
| From the Department of Neurology (A.D.G., S.R.S.), University of
| Neurology. 2008 Jul 30.
DOI Direct Link |
A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
AIMS: Tizanidine, one of the few oral antispastic therapies approved for... | 1st August, 2008
| Medical Affairs Department, Acorda Therapeutics, Inc., Hawthorne, NY, USA.
| Int J Clin Pract. 2008 Feb;62(2):314-24.
DOI Direct Link |
Chondroitin sulfate proteoglycans in spinal cord contusion injury and the effects of chondroitinase treatment.
Chondroitinase treatment of experimental spinal cord injury improves... | 28th February, 2008
| Acorda Therapeutics, Inc., Hawthorne, New York 10532, USA.
| J Neurotrauma. 2007 Nov;24(11):1743-59.
DOI Direct Link |
Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
BACKGROUND: An immediate-release, multiparticulate capsule formulation of... | 8th August, 2007
| Acorda Therapeutics, Inc., Hawthorne, New York 10532, USA.
| Clin Ther. 2007 Apr;29(4):661-9.
DOI Direct Link |
Clinical trials in spinal cord injury.
Progress in promoting axonal plasticity and regeneration in animal models... | 23rd June, 2006
| Acorda Therapeutics, Hawthorne, New York, USA.
| J Neurotrauma. 2006 Mar-Apr;23(3-4):586-93.
DOI Direct Link |
→View more Acorda Therapeutics research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 548 times since April 2007, the link to the organisation's website has been followed 65 times Recent Search Terms used to find this page: acorda therapeutics | acorda ther | acorda therapeutics patent | acorda ther | what is Acorda Therapeutics | t | t | t | acorda and chondroitin sulfate and uk | acorda therapeutics inc | . Search for more companies in Hawthorn Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Acorda Therapeutics |
